Radiation Before Surgery May Help Advanced Kidney Cancer Involving Major Vein
A phase 2 trial at UT Southwestern tested focused radiation on a tumor thrombus before removing the kidney in patients whose kidney cancer had grown into the inferior vena cava. The approach was linked to reduced treatment risks and lower recurrence risk, and one patient's disease was eliminated. Researchers say the findings support further testing of this strategy for this serious complication.
A UT Southwestern phase 2 study enrolled 23 people with kidney cancer extending into the inferior vena cava. Participants received concentrated, high-dose radiation in three or five sessions; 22 then underwent kidney removal and vein tumor extraction four to 14 days afterward. Median follow-up was roughly nine years.
At one year, 71.4% had no recurrence, above the trial's 55.7% historical target. In two of three patients with pre-existing spread, including Diane Gentry, tumors outside the irradiated area shrank—an abscopal immune response. Such IVC tumor thrombi affect an estimated 4% to 10% of kidney cancer patients.
For patients whose kidney cancer reaches the inferior vena cava, this approach could eventually improve how the condition is managed alongside surgery, potentially lowering recurrence and treatment risks. Clinicians and cancer centers may need specialized radiation and surgical expertise to deliver it. Because the trial was small and phase 2, broader benefits, safety, and access remain uncertain until larger studies confirm the findings.